Omalizumab: A useful tool for inducing tolerance to bee venom immunotherapy.
Allergy and Clinical Immunology Unit- University of Messina, Italy.
L
L
Ricciardi
D000293:Adolescent; D000818:Animals; D001514:Bee Venoms / Q000276:immunology*; D001516:Bees / Q000276:immunology; D002648:Child; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D007167:Immunotherapy / Q000379:methods; D007299:Insect Bites and Stings / Q000276:immunology* / Q000628:therapy*; D008297:Male; D000069444:Omalizumab / Q000276:immunology* / Q000627:therapeutic use*
D001514:Bee Venoms; D000069444:Omalizumab
Ann Allergy Asthma Immunol. 2010 Jun;104(6):537-9
20568389
Curr Opin Allergy Clin Immunol. 2013 Feb;13(1):19-24
23242113
Allergy. 2000 Nov;55(11):1005-10
11097308
J Allergy Clin Immunol Pract. 2013 Nov-Dec;1(6):687-8
24565720
Clin Exp Allergy. 2009 Feb;39(2):271-9
19016798
J Allergy Clin Immunol. 2010 Feb;125(2):383-9
20159249
Case Rep Med. 2014;2014:138963
25180038
Immunol Allergy Clin North Am. 2015 May;35(2):287-302
25841552
Cochrane Database Syst Rev. 2012 Oct 17;10:CD008838
23076950
J Investig Allergol Clin Immunol. 2009;19(3):225-9
19610266
Expert Opin Pharmacother. 2011 Nov;12(16):2527-32
21883032
Pediatr Allergy Immunol. 2014 Dec;25(8):829-32
25387446
Allergy. 2007 Aug;62(8):963-4
17484729
Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1):109-12
24674685